KR101964479B1 - 신규 푸라논 유도체 - Google Patents

신규 푸라논 유도체 Download PDF

Info

Publication number
KR101964479B1
KR101964479B1 KR1020137028226A KR20137028226A KR101964479B1 KR 101964479 B1 KR101964479 B1 KR 101964479B1 KR 1020137028226 A KR1020137028226 A KR 1020137028226A KR 20137028226 A KR20137028226 A KR 20137028226A KR 101964479 B1 KR101964479 B1 KR 101964479B1
Authority
KR
South Korea
Prior art keywords
mmol
yield
oxo
carboxylate
solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137028226A
Other languages
English (en)
Korean (ko)
Other versions
KR20140056164A (ko
Inventor
다카유키 이리에
아야코 사와
마사아키 사와
도키코 아사미
요코 후나코시
치카 다나카
Original Assignee
카나 바이오사이언스, 인코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 카나 바이오사이언스, 인코포레이션 filed Critical 카나 바이오사이언스, 인코포레이션
Publication of KR20140056164A publication Critical patent/KR20140056164A/ko
Application granted granted Critical
Publication of KR101964479B1 publication Critical patent/KR101964479B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020137028226A 2011-03-31 2012-03-30 신규 푸라논 유도체 Active KR101964479B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2011-080185 2011-03-31
JP2011080185 2011-03-31
PCT/JP2012/058636 WO2012133802A1 (ja) 2011-03-31 2012-03-30 新規フラノン誘導体

Publications (2)

Publication Number Publication Date
KR20140056164A KR20140056164A (ko) 2014-05-09
KR101964479B1 true KR101964479B1 (ko) 2019-04-01

Family

ID=46931496

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137028226A Active KR101964479B1 (ko) 2011-03-31 2012-03-30 신규 푸라논 유도체

Country Status (12)

Country Link
US (3) USRE48140E1 (https=)
EP (1) EP2692728B1 (https=)
JP (3) JP5659356B2 (https=)
KR (1) KR101964479B1 (https=)
CN (1) CN103459388B (https=)
AU (3) AU2012233246B2 (https=)
BR (1) BR112013024957A2 (https=)
CA (1) CA2830148C (https=)
DK (1) DK2692728T3 (https=)
ES (1) ES2687450T3 (https=)
MX (1) MX344474B (https=)
WO (1) WO2012133802A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2687450T3 (es) 2011-03-31 2018-10-25 Carna Biosciences, Inc. Nuevo derivado de furanona
JP6569908B2 (ja) * 2014-01-31 2019-09-04 カルナバイオサイエンス株式会社 抗がん剤組成物
CN104744353B (zh) * 2015-03-31 2017-11-24 山东友帮生化科技有限公司 2‑氨基‑3‑碘‑5‑氯吡啶的合成方法
CA3042849A1 (en) * 2016-11-04 2018-05-11 Carna Biosciences, Inc. Furanone derivates and methods of use thereof
GB201807147D0 (en) 2018-05-01 2018-06-13 Oncologica Uk Ltd Therapeutic combination
AU2019350581B2 (en) * 2018-09-24 2025-07-10 Carna Biosciences, Inc. Methods of treatment of cancer comprising Cdc7 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001098299A1 (en) 2000-06-19 2001-12-27 Pharmacia Italia S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents
WO2007054508A1 (en) 2005-11-11 2007-05-18 Pfizer Italia Srl Pyrrolopyridines as kinase inhibitors
FR2907120A1 (fr) 2006-10-12 2008-04-18 Sanofi Aventis Sa Nouveaux derives imidazolones,leur preparation a titre de medicaments,compositions pharmaceutiques,utilisation comme inhibiteurs de proteines kinases notamment cdc7

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6987113B2 (en) * 1997-06-11 2006-01-17 Sugen, Inc. Tyrosine kinase inhibitors
BR0312722A (pt) 2002-07-17 2005-05-10 Pharmacia Italia Spa Derivados de pirazol heterobicìclico como inibidores de qinase
US20050137220A1 (en) 2003-07-23 2005-06-23 Pharmacia Corporation Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
US20050043346A1 (en) 2003-08-08 2005-02-24 Pharmacia Italia S.P.A. Pyridylpyrrole derivatives active as kinase inhibitors
JP2007501827A (ja) 2003-08-08 2007-02-01 ファルマシア・イタリア・エス・ピー・エー キナーゼ阻害剤として活性なピリミジルピロール誘導体
FR2876103B1 (fr) 2004-10-01 2008-02-22 Aventis Pharma Sa Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
KR100875870B1 (ko) * 2004-10-14 2008-12-26 에프. 호프만-라 로슈 아게 항암제로서의 신규 아자인돌 티아졸리논
US20060122232A1 (en) * 2004-12-06 2006-06-08 Development Center For Biotechnology 4-Hydroxyfuroic acid derivatives
BRPI0709680B8 (pt) 2006-03-27 2021-05-25 Nerviano Medical Sciences Srl derivados de pirrol, tiofeno e furano substituídos por piridil e piridimil como inibidores de quinase
WO2008109443A2 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting cdk2 gene expression and uses thereof
WO2009155052A1 (en) 2008-05-28 2009-12-23 Wyeth 3-substituted-1h-pyrrolo[2,3-b]pyridine and 3-substituted-1h-pyrrolo[3,2-b]pyridine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
WO2010030727A1 (en) 2008-09-10 2010-03-18 Wyeth Llc 3-substituted-1h-indole, 3-substituted-1h-pyrrolo[2,3-b]pyridine and 3-substituted-1h-pyrrolo[3,2-b]pyridine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
CN102471339A (zh) 2009-07-15 2012-05-23 雅培制药有限公司 激酶的吡咯并吡啶抑制剂
TW201127384A (en) 2009-11-18 2011-08-16 Nerviano Medical Sciences Srl Therapeutic combination comprising a Cdc7 inhibitor and an antineoplastic agent
US20120135989A1 (en) 2010-06-29 2012-05-31 Crystalgenomics, Inc. Azaindole derivative
ES2687450T3 (es) 2011-03-31 2018-10-25 Carna Biosciences, Inc. Nuevo derivado de furanona
JP6569908B2 (ja) 2014-01-31 2019-09-04 カルナバイオサイエンス株式会社 抗がん剤組成物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001098299A1 (en) 2000-06-19 2001-12-27 Pharmacia Italia S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents
WO2007054508A1 (en) 2005-11-11 2007-05-18 Pfizer Italia Srl Pyrrolopyridines as kinase inhibitors
FR2907120A1 (fr) 2006-10-12 2008-04-18 Sanofi Aventis Sa Nouveaux derives imidazolones,leur preparation a titre de medicaments,compositions pharmaceutiques,utilisation comme inhibiteurs de proteines kinases notamment cdc7

Also Published As

Publication number Publication date
CA2830148C (en) 2020-07-28
CN103459388A (zh) 2013-12-18
WO2012133802A1 (ja) 2012-10-04
AU2019203483A1 (en) 2019-06-06
JP5891576B2 (ja) 2016-03-23
MX344474B (es) 2016-12-16
USRE46815E1 (en) 2018-05-01
AU2017203986B2 (en) 2019-02-28
EP2692728A1 (en) 2014-02-05
BR112013024957A2 (pt) 2016-12-20
JP2016084363A (ja) 2016-05-19
EP2692728A4 (en) 2014-08-20
CA2830148A1 (en) 2012-10-04
AU2012233246B2 (en) 2017-03-30
JPWO2012133802A1 (ja) 2014-07-28
JP5659356B2 (ja) 2015-01-28
DK2692728T3 (en) 2018-10-08
ES2687450T3 (es) 2018-10-25
USRE48140E1 (en) 2020-08-04
AU2017203986A1 (en) 2017-07-06
US20140018533A1 (en) 2014-01-16
CN103459388B (zh) 2015-11-25
JP6256927B2 (ja) 2018-01-10
MX2013010962A (es) 2014-04-25
US8742113B2 (en) 2014-06-03
JP2015042663A (ja) 2015-03-05
EP2692728B1 (en) 2018-07-04
AU2012233246A1 (en) 2013-10-10
KR20140056164A (ko) 2014-05-09

Similar Documents

Publication Publication Date Title
CA3054455C (en) Fgfr inhibitor and application thereof
KR101964479B1 (ko) 신규 푸라논 유도체
CN103930408B (zh) 用于癌症治疗的吗啉基苯并三嗪
KR101921764B1 (ko) 피라졸로-퀴놀린
AU2009259867A1 (en) Triazolopyridine JAK inhibitor compounds and methods
KR20160038891A (ko) 신규 축합 피리미딘 화합물 또는 그 염
MX2007007704A (es) Compuestos heterociclicos biciclicos novedosos, procesos para su preparacion y composiciones que los contienen.
EA022064B1 (ru) Гетариламинонафтиридины в качестве ингибиторов атф-связывающих белков
WO2009001021A1 (en) Imidazopyridine derivatives useful as enzyme inhibitors for the treatment of cell proliferative and autoimmune diseases
US20240376076A1 (en) Inhibitors targeting ubiquitin specific protease 7 (usp7)
WO2023185073A1 (zh) Parp7抑制剂及其用途
CN103596953B (zh) 吡啶并萘啶类PI3K和mTOR双重抑制剂及其制备与应用
CN110612302B (zh) 作为激酶JAK抑制剂的吡唑并[1,5-a]嘧啶衍生物
WO2026064705A1 (en) 5/5-5/6-bisaryl compounds as transforming growth factor-β activated kinase inhibitors
HK40083035B (zh) Parp7抑制剂及其用途
KR20220152155A (ko) Ron 돌연변이와 관련된 담도암 예방 또는 치료용 약학 조성물
CA3211149A1 (en) Pharmaceutical compound
WO2020203950A1 (ja) 新規アザインドール誘導体

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20220310

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 8